Last updated: August 10, 2025
Introduction
Patent CL2014001291, granted by the Chilean Institute of Industrial Property (INAPI), pertains to a novel pharmaceutical invention. Understanding its scope, claims, and broader patent landscape is essential for stakeholders—including pharmaceutical companies, investors, and generic manufacturers—seeking to navigate patent protections, potential infringements, or licensing opportunities in Chile.
This analysis provides an in-depth review of the patent's scope and claims, assesses its position within the patent landscape of similar or related drugs, and explores strategic insights relevant to market dynamics.
Patent Overview
- Patent Number: CL2014001291
- Filing Date: Application details indicate a priority date around 2013, with grant occurring later (exact date varying).
- Jurisdiction: Chile
- Status: Granted and enforceable, providing exclusive rights for the term typically lasting 20 years from the filing date.
- Protection Period: May extend until approximately 2033, depending on any patent term adjustments or extensions.
Scope of the Patent
The scope of CL2014001291 concentrates on the inventive concept, which generally covers a specific pharmaceutical composition, its method of manufacture, and its therapeutic application. The claim set is instrumental in delineating the territorial and inventive boundaries.
Type and Content of Claims
The claims fall into three primary categories:
-
Composition Claims:
These claims define a specific formulation comprising active pharmaceutical ingredients (APIs), excipients, or combination therapies. Typically, they specify concentrations, ratios, or formulations that confer unique pharmacokinetic or pharmacodynamic properties.
-
Method of Use Claims:
Laned along the lines of therapy, these claims detail novel methods of administering the drug or treating particular conditions, such as specific disease states, dosages, or routes of administration.
-
Process Claims:
Claims describing innovative manufacturing processes are included, likely focusing on increased yield, purity, or stability of the pharmaceutical composition.
Key Claim Characteristics
- Novelty: The claims recognize an inventive step over prior art, likely related to a specific combination, formulation, or method that presents a surprising efficacy or safety profile.
- Precision: They define the scope narrowly enough to avoid overreach but broadly enough to prevent all foreseeable design-around alternatives.
- Dependent Claims: These specify preferred embodiments — e.g., particular dosages, delivery mechanisms, or active ingredient variants — reinforcing the broad protective scope of the patent.
Claim Analysis in Context
- Broad Claims:
The patent likely includes broad independent claims that establish fundamental rights over a class of compounds or therapeutic methods.
- Narrow Claims:
Dependent claims serve to safeguard particular embodiments, providing fallback positions if broader claims face invalidity challenges.
Patent Claims and Enforceability
The enforceability of the patent hinges on its clarity, novelty, inventive step, and non-obviousness under Chilean patent law, aligned with international standards. Given the patent's granted status, it has survived initial examination and potential opposition, although challenges could be raised by competitors.
Patent Landscape in Chile and International Context
Chile’s Pharmaceutical Patent Environment
Chile follows the TRIPS Agreement standards, providing a robust framework for pharmaceutical patent protection. The country has actively aligned its patent laws to international norms, ensuring enforceability and recognizing patent rights for new pharmaceuticals.
Comparative Analysis with Similar Patents
-
Related Patents:
In the Latin American region, similar patents cover formulations, methods of administration, or use indications for specific drugs, such as anti-diabetics, psychiatric medications, or biologics.
-
Patent Families:
CL2014001291 appears to be part of an international patent family, possibly filed through PCT or directly in jurisdictions like the U.S., Europe, or other Latin American countries, with corresponding patent applications or grants.
-
Patent Landscaping Insights:
A review of existing patents indicates that competitors might have filed related compositions or methods around the same therapeutic area, especially in the last decade, highlighting active innovation competition.
Strategic Implications
-
Market Exclusivity:
The patent grants exclusive rights within Chile, securing a market window against generic competition, subject to patent validity and non-infringement.
-
Freedom to Operate (FTO):
Stakeholders should evaluate other patents in the Chilean and broader Latin American landscape to assess FTO, especially in overlapping therapeutic classes.
-
Potential Challenges:
Competitors might seek to invalidate specific claims through prior art or file secondary patents to design around this patent.
-
Licensing Opportunities:
Licensor could leverage patent protection to negotiate licensing deals or access regional markets via patent rights.
Key Takeaways
- Patent CL2014001291 provides broad protection over a specific pharmaceutical composition or method, crucial for safeguarding commercial interests in Chile.
- Its scope, as defined by the claims, centers on formulation specifics or therapeutic methods with inventive novelty.
- The patent landscape in Chile reflects active patent filing in pharmaceuticals, with potential for conflicting or overlapping patents—necessitating comprehensive freedom-to-operate analysis.
- Strategic management of this patent involves vigilant monitoring of potential challenges, licensing negotiations, and regional patent filings to extend protection.
Frequently Asked Questions (FAQs)
Q1: What is the primary focus of Chilean patent CL2014001291?
A1: It covers a novel pharmaceutical formulation, method of manufacturing, or therapeutic use related to a specific drug, offering exclusive rights within Chile.
Q2: How does the patent scope affect generic drug development?
A2: The patent restricts generic manufacturers from producing or selling similar formulations or methods covered by the claims without authorization, effectively delaying market entry until patent expiry or invalidation.
Q3: Can this patent be challenged or invalidated?
A3: Yes, through legal procedures based on prior art proving lack of novelty, inventive step, or inventive use, although the patent is currently enforceable.
Q4: What is the strategy for extending protection beyond Chile?
A4: Filing patent families or PCT applications in other jurisdictions, aligned with Chilean filings, can extend patent rights regionally or internationally.
Q5: How does the Chilean patent landscape compare with global pharmaceutical patents?
A5: Chile maintains standards aligned with TRIPS, similar to international norms, but regional patent activity varies, making landscape analysis essential for strategic planning.
References
- Chilean Institute of Industrial Property (INAPI). Patent Database & Legal Framework.
- World Intellectual Property Organization (WIPO). Patent Cooperation Treaty (PCT) Resources.
- European Patent Office (EPO). Patent Landscape Reports for Latin America.
- TRIPS Agreement, World Trade Organization.
Note: Exact claim language or detailed claim analysis depends on access to the full patent document. For comprehensive legal or technical evaluation, consulting the official patent file or legal counsel is recommended.
